Marinus Pharma Q2 EPS $(0.63) Misses $(0.59) Estimate, Sales $8.06M Miss $9.49M Estimate
Portfolio Pulse from Benzinga Newsdesk
Marinus Pharma (NASDAQ:MRNS) reported Q2 earnings per share (EPS) of $(0.63), missing the analyst estimate of $(0.59). The company also reported sales of $8.06 million, falling short of the $9.49 million estimate. Despite the misses, sales increased by 32.48% year-over-year.
August 13, 2024 | 11:05 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Marinus Pharma reported Q2 EPS of $(0.63), missing the $(0.59) estimate, and sales of $8.06M, missing the $9.49M estimate. Despite the misses, sales increased by 32.48% YoY.
The company's earnings and sales both missed analyst estimates, which is likely to negatively impact the stock price in the short term. However, the year-over-year sales increase may provide some support.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100